Samarium-153 (Sm-153) stands out as one of the most versatile theranostic radionuclides in modern nuclear medicine, emitting both therapeutic beta particles and diagnostic gamma photons from a single decay pathway. At Protheragen, our multidisciplinary radiochemistry team leverages state-of-the-art facilities and GMP-aligned protocols to deliver precision Sm-153 radiolabeling solutions that bridge the gap between bench-scale discovery and clinical translation.
Samarium-153 is a medium-energy beta-emitting radionuclide with a physical half-life of approximately 46.3 hours (1.93 days), decaying to stable europium-153. Its decay scheme is particularly attractive for theranostic applications: beta particles with average energies of 225 keV and maximum energies reaching 806 keV deliver localized therapeutic doses to targeted tissues, while the simultaneous emission of 103 keV gamma photons (28% abundance) enables real-time SPECT imaging for biodistribution tracking and dosimetry calculations. This dual-emission profile positions Sm-153 as a powerful candidate for personalized radionuclide therapy, where treatment planning and response monitoring can be performed with the same radiopharmaceutical entity.
![Stability test schematic of [153Sm]Sm-DOTA-TATE under different media and temperature conditions](https://www.radiopharmacro.com/wp-content/themes/radiopharmacro/img/4-11-sm-153-radiolabeling-service-1.jpg)
Fig 1. [153Sm]Sm-DOTA-TATE did not show any leaching of 153Sm from the chelator in PBS at 37 °C, human serum at 37 °C and radiolabeling buffer at RT for at least 7 days. RT = room temperature. (Van de Voorde, Michiel., 2022)
The radiolabeling of Sm-153 typically involves chelation chemistry using macrocyclic ligands such as DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) or acyclic polyphosphonates such as EDTMP and DOTMP. These chelators form highly stable complexes with the trivalent samarium ion (Sm³⁺), ensuring minimal transchelation or leakage under physiological conditions. Recent advances in high-specific-activity Sm-153 production—achieved through neutron activation of enriched ¹⁵²Sm targets followed by mass separation—have unlocked new possibilities for receptor-targeted radionuclide therapy, expanding the isotope's utility well beyond its traditional role in bone pain palliation.
Protheragen operates as a full-spectrum Radiopharmaceutical CRDMO and CRO, offering end-to-end Sm-153 radiolabeling capabilities that span from early-phase radiochemistry optimization through GMP-compliant manufacturing and clinical trial support. Whether your program requires the development of a novel bone-seeking phosphonate conjugate, a peptide-targeted theranostic for neuroendocrine tumors, or a nanoparticle-based delivery system, our integrated platform accelerates your path from concept to clinic. With dedicated hot laboratories, validated analytical suites, and experienced regulatory strategists, we ensure that every Sm-153-labeled candidate meets the stringent quality and safety standards demanded by both preclinical studies and IIT clinical investigations.
We perform Sm-153 chelation with DOTA, DTPA, EDTMP, DOTMP, and other bespoke ligands, optimizing reaction conditions (pH, temperature, molar ratio) to achieve radiochemical purity exceeding 95% for preclinical and clinical-grade batches.
Our team specializes in site-specific conjugation of Sm-153 to somatostatin analogues (e.g., DOTA-TATE), antibody fragments, and scaffold proteins, preserving biological activity while ensuring robust metal chelate stability in serum and plasma.
We develop Sm-153-labeled polymeric microspheres, iron oxide nanoparticles, and calcium phosphate nanocarriers for applications in radioembolization, multimodal imaging, and localized drug delivery platforms.
Leveraging our expertise in phosphonate chemistry, we design and radiolabel next-generation bone-seeking agents such as ¹⁵³Sm-DOTMP, offering improved skeletal uptake kinetics and reduced off-target distribution compared to legacy EDTMP formulations.
Every batch undergoes comprehensive quality control including iTLC-SG, HPLC, and radio-HPLC analysis, with accelerated stability studies in relevant media (PBS, human serum, plasma) to confirm integrity over the isotope's 46.3-hour half-life.
We conduct SPECT/CT imaging, gamma counting, and organ dosimetry in rodent and large-animal models, generating the pharmacokinetic and radiation dose data required for IND-enabling toxicology packages and clinical trial design.
Our Sm-153 radiolabeling workflow is designed to ensure reproducibility, regulatory compliance, and seamless translation from research-grade to clinical-grade production. Each project follows a structured pathway tailored to the specific chelator, targeting vector, and intended application.
1. Project Consultation & Feasibility Assessment: We begin with a detailed review of your molecular target, desired specific activity, and intended clinical indication. Our radiochemistry team evaluates ligand selection, predicted stability, and regulatory strategy to define a clear project scope and timeline.
2. Ligand Synthesis & Characterization: The cold chelator or bioconjugate is synthesized or procured, then characterized by NMR, mass spectrometry, and HPLC to confirm identity and purity prior to radiolabeling.
3. Sm-153 Source Preparation & Quality Verification: Sm-153 chloride is received from qualified suppliers or produced in-house, then verified for radionuclidic purity, specific activity, and chemical identity via gamma spectroscopy and chromatographic analysis.
4. Radiolabeling Reaction Optimization: Chelation conditions—including buffer composition (typically sodium acetate, pH 4.5–5.5), reaction temperature (60–95°C), and ligand-to-metal molar ratio—are systematically optimized to maximize radiochemical yield and purity.
5. Purification & Quality Control: The labeled product is purified via solid-phase extraction, size-exclusion chromatography, or HPLC, followed by rigorous QC testing: radiochemical purity (iTLC-SG, HPLC), specific activity, pH, osmolality, endotoxin, and sterility.
6. Stability Validation: In vitro stability is assessed in physiologically relevant media (PBS, human serum, plasma) over 24–72 hours, with time-point sampling to confirm resistance to transchelation, protein binding, and degradation.
7. Preclinical Biological Evaluation (Optional): For comprehensive programs, we perform cell-binding assays, internalization studies, and biodistribution imaging in xenograft or orthotopic models to validate targeting specificity and therapeutic potential.
8. Documentation & Regulatory Support: Complete batch records, CoA, stability reports, and radiation safety data are compiled to support IND/CTA filings, investigator brochures, and institutional review board submissions.
Ready to advance your Sm-153 radiopharmaceutical program? Whether you are exploring a novel theranostic concept, preparing for an IIT clinical trial, or scaling toward commercial production, Protheragen is equipped to support every stage of your journey. Reach out to us today to discuss your project requirements, receive a customized proposal, and discover how our radiochemistry expertise can accelerate your path from molecule to medicine. Contact us now and let our team turn your Sm-153 radiolabeling vision into a clinical reality.
Reference